Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management

NCT00431496 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00431496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2006
Completion date
October 31, 2009
Enrollment
71 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, secondary hyperparathyroidism